Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)” (EBioMedicine (2020) 55, (S2352396420301547), (10.1016/j.ebiom.2020.102779))

1. De Miguel, R.
2. Rial-Crestelo, D.
3. Dominguez-Dominguez, L.
4. Montejano, R.
5. Esteban-Cantos, A.
6. Aranguren-Rivas, P.
7. Stella-Ascariz, N.
8. Bisbal, O.
9. Bermejo-Plaza, L.
10. Garcia-Alvarez, M.
11. Alejos, B.
12. Hernando, A.
13. Santacreu-Guerrero, M.
14. Cadiñanos, J.
15. Mayoral, M.
16. Castro, J.M.
17. Moreno, V.
18. Martin-Carbonero, L.
19. Delgado, R.
20. Rubio, R.
21. Pulido, F.
22. Arribas, J.R.